查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1827611

女性健康诊断市场按适应症、检测类型、技术、最终用户、样本类型和分销管道划分—2025-2032 年全球预测

Women's Health Diagnostics Market by Disease Indication, Test Type, Technology, End User, Sample Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，女性健康诊断市场规模将成长至 984.3 亿美元，复合年增长率为 9.73%。

主要市场统计数据
基准年2024年 468.2亿美元
预计2025年 514.3亿美元
预测年份：2032年 984.3亿美元
复合年增长率（%） 9.73%

全面说明目前影响女性健康筛检的动态，重点在于临床重点、技术融合和相关人员

在日益融合的临床需求、技术创新和不断变化的医疗服务模式的推动下，女性健康诊断领域正在经历持续的变化。临床医生、实验室负责人和政策制定者正重新重视针对慢性病、感染疾病预防、代谢管理、癌症筛检和生殖健康的早期发现、持续监测和以患者为中心的检测策略。这些优先事项迫使诊断开发人员提供兼具临床灵敏度、简化工作流程和经济实惠性的检测方法和平台。

同时，分子检测法、免疫检测、生化分析和数位医疗领域的进步正在扩大可行诊断的范围，超越传统的中心实验室模式。这些能力，加上分散式检测、远端医疗整合以及日益增多的照护现场部署等营运趋势，强化了对强大的数据互通性和清晰的监管策略的需求。因此，在该领域运作的公司必须同时管理产品创新、製造弹性和市场准入，以满足临床医生的期望和患者的需求。

随着支付方和监管机构对临床效用和实际表现的审查日益严格，开发人员不仅必须检验分析准确性，还必须验证其对下游结果和工作流程的影响。这些因素的共同作用，为寻求扩展解决方案以有效改善女性在整个护理过程中的健康状况的利益相关人员带来了机会和复杂性。

改变女性健康诊断服务的关键颠覆性力量包括权力下放、分子创新、数位智慧和监管压力

近期趋势揭示了若干变革性变化，这些变化正在重塑女性健康诊断技术的开发、应用和报销方式。科技的普及降低了照护现场设备和携带式平台的进入门槛，使得怀孕和不孕症标记检测以及传染病筛检更加便捷。同时，在PCR工作流程改进和次世代定序方法引入的推动下，分子诊断技术正在为肿瘤学和感染疾病管理提供更高解析度的洞察，促使人们重新评估诊断演算法。

数据分析和人工智慧也在改变价值提案。演算法分类、多模态数据中的模式识别以及软体驱动的决策支援正在提高复杂检测的可解释性，并实现筛检间隔。不断变化的法规和日益严格的付款人审查，同时迫使製造商更早投入，以产生真实世界证据，并展示超越传统绩效指标的临床效用和经济价值。地缘政治和供应链的考量正在进一步推动区域製造策略和供应商多元化，从而减少对单一来源的依赖。

由此产生的竞争格局将惠及那些能够将强大的检测能力与精简的工作流程、清晰的监管途径和可扩展的分销模式相结合的机构。总而言之，这种转变为跨部门合作、策略伙伴关係和定向投资创造了机会，使诊断创新与医疗保健服务的现实相契合。

评估2025年关税对供应链、製造地决策、定价和采购行为的累积影响

2025年的关税措施代表着重要的商业背景，正在再形成诊断製造商和经销商的供应链经济、采购行为和采购决策。某些类别的仪器和试剂进口关税的提高，推高了依赖跨境製造的仪器和套件的到岸成本，给那些从国际采购零件的公司带来了直接的利润压力。医院、诊断中心和经销商的采购团队正在采取应对措施，加强供应商资格认证流程，并重新评估整体拥有成本，以在限制价格上涨的同时维持服务水准。

为了应对这项挑战，一些製造商正在加快近岸外包和在岸外包的步伐，以保护关键生产环节免受关税波动的影响。这种转变不仅改变了资本规划和位置，也影响了零件供应和契约製造的策略伙伴关係关係。定价策略也进行了调整，以平衡报销现实与维持创新投资的需求，从而与付款人进行更细緻的商业性对话，将定价与临床效果和营运效率联繫起来。

在营运方面，不断变化的关税环境提升了模组化平台设计和试剂规格的价值，从而实现跨区域灵活生产。此外，库存视觉性和需求平衡机制也日益重要，有助于缓解短期供应中断。展望未来，在贸易紧张和监管环境不断演变的环境下，积极拓展供应商网络、尽可能实现本地化生产并加强合约保护的利益相关人员将更有能力保持产品供应并保护利润。

策略性细分洞察揭示了疾病适应症、检测类型、技术、最终用户、样本类型和分销管道如何影响机会和采用

深入的细分揭示了需求驱动因素和技术选择如何因疾病状态、检测形式和护理环境而异。在考虑疾病适应症时，心血管疾病、感染疾病、代谢性疾病、肿瘤学和怀孕/不孕症的优先顺序有所不同；感染疾病着重于爱滋病毒和人类乳突病毒筛检；代谢管理着重于糖尿病和甲状腺疾病；肿瘤学投资着重于乳癌、子宫颈癌和卵巢癌的检测；生殖健康需要便捷的排卵和怀孕检测。这些临床差异影响诊断所需的灵敏度、週转时间和整合需求，并相应地塑造产品蓝图。

检测类型进一步将市场机会细分为仪器、套件、试剂、软体和服务。仪器包括桌上型和照护现场类型；套件和试剂包括免疫测量、横向流动化验和分子诊断套件；软体和服务包括支援结果解读和工作流程编排的资讯学软体和服务。技术选择涵盖比色法和萤光法等生化测定、免疫检测以及PCR和次世代定序等分子诊断，决定了分析性能、成本结构和易用性，从而影响不同最终用户的采用曲线。

最终用户本身涵盖居家医疗机构、医院、诊断中心和研究实验室，每个机构都有其独特的采购週期、研究预期和营运限制。检体类型（血液、唾液、组织、尿液等）的考量决定了采集物流和检测设计，而分销管道（直销、分销商和线上管道）的动态则主导着产品上市和客户参与策略。整合这些细分视角，可以实现更精准的产品定位、更有针对性的临床检验，以及反映临床工作流程和付款人需求的最佳商业化计画。

区域比较洞察显示法律规范、报销实践和本地製造如何影响全球主要地区的诊断采用

法律规范、支付系统和临床实践模式的地区差异，导緻美洲、欧洲、中东和非洲以及亚太地区的商业化路径截然不同。美洲通常受益于成熟的报销机制和强大的私人诊断市场，一旦临床效用得到证实，便可以相对快速地部署照护现场设备和新型分子检测。该地区的采购通常强调与电子健康记录和支援大型医疗保健系统的扩充性服务模式的整合。

欧洲、中东和非洲的环境更多元化，监管流程和报销模式各异，需要在国家层级采取因地制宜的方案。一些欧洲市场可能透过协调监管和统一的临床评估途径来简化实施流程，而中东和北非市场则可能优先考虑经济高效的筛检解决方案和能力建立伙伴关係，以扩大可及性。相关人员通常会寻求公私合营，以加快在资源匮乏地区的部署。

亚太地区正经历已开发市场技术快速应用的快速发展，新兴经济体对价格合理、可扩展的诊断技术的需求也十分强劲。政府主导的倡议加强本地製造能力和国内供应伙伴关係的倡议是关键驱动因素，而与区域经销商的合作对于应对复杂的市场准入要求通常至关重要。在所有地区，了解监管时机、报销途径和临床指南之间的相互作用对于有效的市场规划和持续应用至关重要。

领先的诊断公司如何协调平台多样化、试剂策略、数位服务和製造伙伴关係以保持成长和差异化

诊断生态系统中的主要企业正在采取各种策略来应对竞争压力和临床需求。仪器製造商优先考虑支援中央实验室和照护现场流程的模组化平台，使其能够透过一致的耗材生态系统服务众多最终用户。试剂和试剂套件製造商正在精简其产品组合，转向免疫测量和横向流动装置等大容量检测方式，同时投资于利用简化工作流程进行分散式检查的分子试剂套件。

软体和服务供应商正凭藉其连结性、决策支援和真实世界证据能力脱颖而出，这些能力有助于他们向临床医生和付款人展示其价值。整合数据分析和临床检验程序的公司在支持付款人报销谈判和大型医疗系统采用方面具有优势。同时，对于寻求减轻关税影响并确保灵活生产能力的公司而言，製造外包製造商和区域合作伙伴正变得越来越重要。

策略合作、授权协议和选择性收购仍然是快速填补能力缺口的常用机制，例如专业化检测化学、数位健康专业知识和区域分销网路。那些将研发投资与清晰的临床效用路径结合，并在生产和商业营运中保持严格执行的组织，最有能力将创新转化为可扩展的业务成果。

为产业领导者提供切实可行的建议，以加强其供应链、加速平台采用、实现数据收益并优化其市场路线

产业领导者应采取一系列协同行动，抓住新机会，同时降低下行风险。首先，透过多元化采购、选择性近岸外包以及包含品质和交付保障措施的长期供应商协议，优先提升供应链韧性。加强库存透明度和需求预测流程，将降低受关税主导的成本衝击和零件短缺影响的风险。其次，投资平台模组化和试剂标准化，将加快新检测方法的上市时间，并以最少的检验实现跨市场部署。

第三，我们透过建构支持结果解读、疗效追踪和证据产生的互通软体，将数据策略融入产品开发。透过真实世界证据证明临床效用对于有利的报销讨论和处方集收录至关重要。第四，我们根据居家医疗、医院、诊断中心和实验室的需求客製化产品功能，并选择能够最大程度扩大覆盖范围并控制客户体验的销售管道，从而客製化我们的市场推广策略。最后，我们与临床网路、公共卫生组织和区域製造商建立策略伙伴关係，以提高采用率、共用担风险并加速规模化，同时满足当地监管和付款方的要求。

采用初步访谈、二次综合、资料三角测量、分割架构和品管等调查方法来指导分析

支撑这些见解的研究将定性专家参与与系统的二次分析相结合，以确保研究的深度和广度。初步研究包括对临床医生、实验室主任、采购专业人员和行业高管的结构化访谈，以了解临床需求、工作流程限制和应用驱动因素等领域的观点。二次分析综合了监管指南、报销政策和近期同行评审文献，以彙编临床和技术趋势。

采用资料三角测量法来协调不同观点，并检验不同资讯来源的主题结论。疾病指征、检测类型、技术、最终用户、样本类型和分销管道的细分框架指导了访谈指南和比较分析。品管方法包括访谈记录的交叉检验、主题编码的独立审查以及检测方法技术说明的检验。局限性包括监管时间表和不断变化的关税政策的地区差异，这些局限性通过定性解释中基于情景的敏感性来解释。这种方法强调透明度和调查方法的严谨性，以支持决策者得出可行的结论。

综合结论，提取有关该领域的技术趋势、临床重点、商业性挑战和策略要点的可行见解

摘要：女性健康诊断领域正朝着更分散化、数据驱动、临床导向的解决方案转型，以满足传染病筛检、代谢监测、癌症检测和生殖健康等领域的持续需求。分子诊断、免疫检测和生化分析领域的技术进步扩展了诊断能力，而数位化工具则增强了解读和护理整合。同时，政策变化、付款人预期以及关税等贸易动态正迫使製造商调整其生产布局、证据生成策略和商业性模式。

相关人员若能将产品设计与检验的临床效用结合，推行弹性供应链策略，并采用可互通的数位服务，将能够更好地将技术创新转化为患者照护的重大改进。那些将科学严谨性与製造、监管和商业领域的实际执行力相结合，能够在不断发展的女性健康检测领域产生持久影响的组织，将占据优势地位。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 具有人工智慧功能的可穿戴怀孕追踪设备可提供个人化的排卵和週期预测，需求量很大
  • 在医疗资源匮乏的地区，基于远端医疗的早期子痫前症筛检就地检验的快速扩展
  • 整合非侵入性产前液态生物检体检测，全面检测胎儿基因异常
  • 采用个人化多激素分析诊断来制定个人化的更年期管理计划
  • 开发用于同时检测多种性行为感染病原体的快速多重分子平台
  • 家用子宫内膜容受性测试的出现提高了 IVF 週期的植入成功率
  • 推出结合家庭样本采集套件的远端监控解决方案，用于女性心血管风险评估

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章：女性健康体检市场（依疾病类型划分）

  • 心血管疾病
  • 感染疾病
    • HIV
    • 人类乳突病毒
  • 代谢紊乱
    • 糖尿病
    • 甲状腺疾病
  • 肿瘤学
    • 乳癌
    • 子宫颈癌
    • 卵巢癌
  • 怀孕和生育能力
    • 排卵测试
    • 妊娠试验

9. 女性健康检查市场（按检查类型）

  • 装置
    • 桌上型装置
    • 照护现场设备
  • 套件和试剂
    • 免疫检测
    • 横向流动化验
    • 分子诊断试剂套件
  • 软体和服务
    • 资讯软体
    • 服务

第 10 章：女性健康检查市场（按技术）

  • 生化分析
    • 比色分析
    • 萤光测量
  • 免疫检测
  • 分子诊断
    • 次世代定序
    • PCR

第 11 章：女性健康体检市场（依最终使用者）

  • 居家照护环境
  • 医院和诊断中心
  • 研究办公室

第 12 章：女性健康体检市场（依样本类型）

  • 血
  • 唾液
  • 组织
  • 尿

第十三章女性健康体检市场（依通路）

  • 直销
  • 经销商
  • 线上管道

第14章：女性健康体检市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 女性健康体检市场（依群体）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：各国女性健康体检市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • AccuBioTech Co., Ltd.
    • Becton, Dickinson and Company
    • Biomerieux SA
    • Cardinal Health, Inc.
    • Carestream Health, Inc.
    • Chembio Diagnostic Systems, Inc.
    • Cook Medical, Inc.
    • Danaher Corporation
    • DIALAB GmbH
    • EKF Diagnostics Holdings PLC
    • F. Hoffmann-La Roche Ltd.
    • FUJIFILM Holdings Corporation
    • GE Healthcare
    • Guided Therapeutics, Inc.
    • Hologic, Inc.
    • Koninklijke Philips NV
    • MedGyn Products, Inc.
    • NeuroLogica Corporation
    • Nova Biomedical
    • Perkinelmer Inc.
    • Quest Diagnostics Incorporated
    • Siemens AG
    • SuperSonic Imagine
    • Werfen, SA
    • OSI Systems, Inc.
    • Hill-Rom Holdings, Inc.
    • Bio-Rad Laboratories, Inc.
    • Sekisui Diagnostics, LLC
    • Thermo Fisher Scientific Inc.
Product Code: MRR-43477954269C

The Women's Health Diagnostics Market is projected to grow by USD 98.43 billion at a CAGR of 9.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 46.82 billion
Estimated Year [2025] USD 51.43 billion
Forecast Year [2032] USD 98.43 billion
CAGR (%) 9.73%

A comprehensive orientation to the current dynamics shaping women's health diagnostics with emphasis on clinical priorities, technology convergence, and stakeholder responsibilities

The landscape of women's health diagnostics is undergoing a period of sustained transition driven by converging clinical needs, technological innovation, and changing care delivery models. Clinicians, laboratory leaders, and policy makers are placing renewed emphasis on earlier detection, ongoing monitoring, and patient-centric testing strategies that address chronic conditions, infectious disease prevention, metabolic management, oncology screening, and reproductive health. These priorities exert pressure on diagnostic developers to deliver assays and platforms that combine clinical sensitivity with streamlined workflows and affordability.

Meanwhile, advances in molecular methods, immunoassays, biochemical analytics, and digital health are expanding the range of feasible diagnostics beyond traditional central laboratory paradigms. These capabilities are married to operational trends such as decentralization of testing, telehealth integration, and expanded point-of-care deployment, reinforcing the need for robust data interoperability and clear regulatory strategies. As a result, organizations operating in this space must simultaneously manage product innovation, manufacturing resilience, and market access pathways to meet clinician expectations and patient needs.

Because payers and regulators increasingly scrutinize clinical utility and real-world performance, developers must validate not only analytical accuracy but also downstream outcomes and workflow impacts. Taken together, these forces herald both opportunity and complexity for stakeholders seeking to scale solutions that meaningfully improve health outcomes for women across the care continuum.

Key disruptive forces transforming diagnostics delivery for women's health including decentralization, molecular innovation, digital intelligence, and regulatory pressure

Recent years have revealed several transformative shifts that are reshaping how diagnostics for women's health are developed, adopted, and reimbursed. Technological democratization has lowered barriers to entry for point-of-care instruments and portable platforms, enabling closer-to-patient testing for pregnancy and fertility markers as well as for infectious disease screening. At the same time, molecular diagnostics-driven by improvements in PCR workflows and adoption of next generation sequencing approaches-are producing higher-resolution insights for oncology and infectious disease management, prompting a reassessment of diagnostic algorithms.

Data analytics and artificial intelligence are also altering value propositions. Algorithmic triage, pattern recognition across multimodal data, and software-enabled decision support enhance the interpretability of complex assays and enable personalization of screening intervals. Concurrent regulatory evolution and payer scrutiny are prompting manufacturers to invest earlier in real-world evidence generation, demonstrating clinical utility and economic value beyond conventional performance metrics. Geopolitical and supply chain considerations have further accelerated regional manufacturing strategies and supplier diversification to reduce exposure to single-source dependencies.

As a result, the competitive environment rewards organizations that can integrate robust assay performance with streamlined workflows, clear regulatory pathways, and scalable distribution models. These shifts collectively create openings for cross-sector collaboration, strategic partnerships, and targeted investments that align diagnostic innovation with the practical realities of care delivery.

Assessing the cumulative implications of 2025 tariff actions on supply chains, manufacturing location decisions, pricing dynamics, and procurement behavior

The tariff measures implemented in 2025 present a material operating context that has reshaped supply chain economics, procurement behavior, and sourcing decisions for diagnostic manufacturers and distributors. Increased import duties on certain categories of instruments and reagents have elevated landed costs for devices and kits that rely on cross-border manufacturing, creating immediate margin pressure for firms that source components internationally. Procurement teams across hospitals, diagnostic centers, and distributors have responded by intensifying supplier qualification processes and re-evaluating total cost of ownership to retain service levels while limiting price escalation.

In response, several manufacturers have accelerated nearshoring and onshoring initiatives to insulate critical production stages from tariff volatility. This shift has not only altered capital planning and site selection but also influenced strategic partnerships for component supply and contract manufacturing. Pricing strategies have been adjusted to balance reimbursement realities with the need to preserve investment in innovation, prompting more nuanced commercial conversations with payers that link pricing to demonstrated clinical impact and operational efficiencies.

Operationally, the tariff environment has increased the value of modular platform designs and reagent formats that enable flexible manufacturing across geographies. It has also elevated the importance of inventory visibility and demand-smoothing mechanisms to mitigate short-term supply disruptions. Looking ahead, stakeholders that proactively diversify supplier networks, localize production where feasible, and strengthen contractual protections will be better positioned to sustain product availability and protect margin in an environment marked by trade friction and evolving regulatory landscapes.

Strategic segmentation insights clarifying how disease indications, test types, technologies, end users, sample types, and distribution channels shape opportunity and adoption

Insightful segmentation reveals how demand drivers and technology choices vary across disease states, test formats, and care settings. When considering disease indication, priorities differ between cardiovascular conditions, infectious diseases, metabolic disorders, oncology, and pregnancy and fertility, with infectious diseases receiving focused attention on HIV and human papillomavirus screening, metabolic management emphasizing diabetes and thyroid disorders, oncology investments targeting breast, cervical, and ovarian cancer detection, and reproductive health requiring accessible ovulation and pregnancy tests. These clinical distinctions influence the required sensitivity, turnaround time, and integration needs for diagnostics, and they shape product roadmaps accordingly.

Test type distinctions further refine market opportunities across instruments, kits and reagents, and software and services. Instruments vary between benchtop and point-of-care systems, while kits and reagents encompass immunoassays, lateral flow assays, and molecular diagnostics kits, and software and services include informational software and services that support result interpretation and workflow orchestration. Technology choices-spanning biochemical analysis modalities such as colorimetry and fluorometry, immunoassays, and molecular diagnostics including PCR and next generation sequencing-determine analytical performance, cost structure, and usability profiles, and therefore influence adoption curves across different end users.

End users themselves span home care settings, hospital and diagnostic centers, and research laboratories, each with unique procurement cycles, regulatory expectations, and operational constraints. Sample type considerations such as blood, saliva, tissue, and urine shape collection logistics and test design, while distribution channel dynamics across direct sales, distributors, and online channels govern market access and customer engagement strategies. Integrating these segmentation lenses enables more precise product positioning, targeted clinical validation, and optimized commercialization plans that reflect distinct clinical workflows and payer demands.

Comparative regional insights highlighting how regulatory frameworks, reimbursement practices, and local manufacturing shape diagnostics adoption across major global regions

Regional variation in regulatory frameworks, payer systems, and clinical practice patterns produces materially different commercialization pathways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, adoption commonly benefits from mature reimbursement mechanisms and a strong private diagnostics market, enabling relatively rapid uptake of point-of-care instruments and novel molecular assays when demonstrable clinical utility exists. Procurement in this region often emphasizes integration with electronic health records and scalable service models that support large health systems.

Europe, Middle East & Africa presents a more heterogeneous environment with divergent regulatory processes and reimbursement models, requiring tailored country-level approaches. Regulatory harmonization efforts and centralized clinical evaluation pathways in some European markets can streamline adoption, while markets in the Middle East and Africa may prioritize cost-effective screening solutions and capacity-building partnerships to expand access. Stakeholders frequently pursue public-private collaborations to accelerate deployment in under-resourced settings.

Asia-Pacific demonstrates a mix of rapid technological uptake in advanced markets and strong demand for affordable, scalable diagnostics across emerging economies. Local manufacturing capabilities and government-led initiatives to strengthen domestic supply chains are important dynamics, and partnerships with regional distributors are often critical to navigate complex market entry requirements. Across all regions, understanding the interplay between regulatory timing, reimbursement pathways, and clinical guidelines remains essential for effective market planning and sustainable adoption.

How leading diagnostics companies are aligning platform diversification, reagent strategy, digital services, and manufacturing partnerships to sustain growth and differentiation

Leading players across the diagnostics ecosystem are pursuing a range of strategic responses to competitive pressure and clinical demand. Instrument manufacturers are prioritizing modular platforms that support both central laboratory and point-of-care workflows, enabling them to serve multiple end users with a consistent consumable ecosystem. Reagent and kit producers are streamlining portfolio rationalization toward high-volume assay formats like immunoassays and lateral flow devices while investing in molecular kits that leverage simplified workflows for decentralized testing.

Software and service providers are differentiating through connectivity, decision support, and real-world evidence capabilities that help demonstrate value to clinicians and payers. Companies that integrate data analytics with clinical validation programs gain an advantage when negotiating payer reimbursement and when supporting adoption among large health systems. At the same time, contract manufacturers and regional partners are becoming more important as organizations seek to mitigate tariff exposure and secure flexible production capacity.

Strategic collaborations, licensing arrangements, and selectively targeted acquisitions remain common mechanisms to fill capability gaps quickly, whether for specialized assay chemistries, digital health expertise, or regional distribution networks. Organizations that align R&D investments with clear pathways to clinical utility and that maintain disciplined execution across manufacturing and commercial operations are best positioned to translate innovation into scalable business performance.

Actionable recommendations for industry leaders to strengthen supply chains, accelerate platform adoption, monetize data, and optimize market entry pathways

Industry leaders should enact a set of coordinated actions to capture emerging opportunities while reducing downside risk. First, prioritize supply chain resilience through diversified sourcing, selective nearshoring, and long-term supplier agreements that include quality and delivery safeguards. Strengthening inventory transparency and demand forecasting processes will reduce vulnerability to tariff-driven cost shocks and component shortages. Second, invest in platform modularity and reagent standardization to accelerate time-to-market for new assays and enable cross-market deployment with minimal revalidation.

Third, embed data strategies into product development by building interoperable software that supports result interpretation, outcomes tracking, and evidence generation. Demonstrating clinical utility through real-world evidence will be critical for favorable reimbursement discussions and formulary inclusion. Fourth, tailor market entry approaches by aligning product features with the needs of home care settings, hospital and diagnostic centers, and research laboratories, and by selecting distribution channels that maximize reach while controlling customer experience. Finally, pursue strategic partnerships with clinical networks, public health bodies, and regional manufacturers to amplify adoption, share risk, and accelerate scale while meeting local regulatory and payer requirements.

Research methodology describing primary interviews, secondary synthesis, data triangulation, segmentation frameworks, and quality controls that inform the analysis

The research underpinning these insights combined qualitative expert engagement with systematic secondary analysis to ensure both depth and breadth. Primary research involved structured interviews with clinicians, laboratory directors, procurement specialists, and industry executives to capture frontline perspectives on clinical needs, workflow constraints, and adoption drivers. Secondary analysis synthesized regulatory guidance, reimbursement policies, and recent peer-reviewed literature to contextualize clinical and technological trends.

Data triangulation was applied to reconcile differing viewpoints and to validate thematic conclusions across sources. Segmentation frameworks for disease indication, test type, technology, end user, sample type, and distribution channel guided interview targeting and comparative analysis. Quality control measures included cross-validation of interview transcripts, independent review of thematic coding, and verification of technical descriptions for assay methodologies. Limitations include variability in regional regulatory timelines and evolving tariff policies, which were accounted for through scenario-based sensitivity in qualitative interpretation. The approach emphasized transparency and methodological rigor to support actionable conclusions for decision-makers.

Concluding synthesis that distills actionable insights on technological trends, clinical priorities, commercial challenges, and strategic imperatives for the sector

In summary, the women's health diagnostics arena is moving toward more decentralized, data-enabled, and clinically focused solutions that respond to persistent needs in infectious disease screening, metabolic monitoring, oncology detection, and reproductive health. Technological advances in molecular diagnostics, immunoassay chemistry, and biochemical analysis are expanding diagnostic capability, while digital tools enhance interpretation and care integration. Meanwhile, policy shifts, payer expectations, and trade dynamics such as tariffs require manufacturers to adapt manufacturing footprints, evidence generation strategies, and commercial approaches.

Stakeholders that align product design with validated clinical utility, pursue resilient supply chain strategies, and embrace interoperable digital services will be well positioned to translate technical innovation into meaningful improvements in patient care. The path forward favors organizations that combine scientific rigor with pragmatic execution across manufacturing, regulatory, and commercial domains, enabling sustained impact in the evolving field of women's health diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing demand for AI-enabled fertility tracking wearables providing personalized ovulation and cycle predictions
  • 5.2. Rapid expansion of telehealth-based point-of-care tests for early preeclampsia screening in underserved communities
  • 5.3. Integration of non-invasive prenatal liquid biopsy assays for comprehensive fetal genetic anomaly detection
  • 5.4. Adoption of personalized multi-hormone profiling diagnostics to tailor individualized menopause management plans
  • 5.5. Development of rapid multiplex molecular platforms for simultaneous detection of multiple sexually transmitted pathogens
  • 5.6. Emergence of at-home endometrial receptivity tests improving implantation success rates in in vitro fertilization cycles
  • 5.7. Implementation of telemonitoring solutions combined with at-home sampling kits for cardiovascular risk assessment in women

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Women's Health Diagnostics Market, by Disease Indication

  • 8.1. Cardiovascular Conditions
  • 8.2. Infectious Diseases
    • 8.2.1. HIV
    • 8.2.2. Human Papillomavirus
  • 8.3. Metabolic Disorders
    • 8.3.1. Diabetes
    • 8.3.2. Thyroid Disorders
  • 8.4. Oncology
    • 8.4.1. Breast Cancer
    • 8.4.2. Cervical Cancer
    • 8.4.3. Ovarian Cancer
  • 8.5. Pregnancy And Fertility
    • 8.5.1. Ovulation Test
    • 8.5.2. Pregnancy Test

9. Women's Health Diagnostics Market, by Test Type

  • 9.1. Instruments
    • 9.1.1. Benchtop Instruments
    • 9.1.2. Point Of Care Instruments
  • 9.2. Kits And Reagents
    • 9.2.1. Immunoassays
    • 9.2.2. Lateral Flow Assays
    • 9.2.3. Molecular Diagnostics Kits
  • 9.3. Software And Services
    • 9.3.1. Informational Software
    • 9.3.2. Services

10. Women's Health Diagnostics Market, by Technology

  • 10.1. Biochemical Analysis
    • 10.1.1. Colorimetry
    • 10.1.2. Fluorometry
  • 10.2. Immunoassay
  • 10.3. Molecular Diagnostics
    • 10.3.1. Next Generation Sequencing
    • 10.3.2. PCR

11. Women's Health Diagnostics Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospital And Diagnostic Centers
  • 11.3. Research Laboratories

12. Women's Health Diagnostics Market, by Sample Type

  • 12.1. Blood
  • 12.2. Saliva
  • 12.3. Tissue
  • 12.4. Urine

13. Women's Health Diagnostics Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Distributors
  • 13.3. Online Channels

14. Women's Health Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Women's Health Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Women's Health Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories
    • 17.3.2. AccuBioTech Co., Ltd.
    • 17.3.3. Becton, Dickinson and Company
    • 17.3.4. Biomerieux SA
    • 17.3.5. Cardinal Health, Inc.
    • 17.3.6. Carestream Health, Inc.
    • 17.3.7. Chembio Diagnostic Systems, Inc.
    • 17.3.8. Cook Medical, Inc.
    • 17.3.9. Danaher Corporation
    • 17.3.10. DIALAB GmbH
    • 17.3.11. EKF Diagnostics Holdings PLC
    • 17.3.12. F. Hoffmann-La Roche Ltd.
    • 17.3.13. FUJIFILM Holdings Corporation
    • 17.3.14. GE Healthcare
    • 17.3.15. Guided Therapeutics, Inc.
    • 17.3.16. Hologic, Inc.
    • 17.3.17. Koninklijke Philips N.V.
    • 17.3.18. MedGyn Products, Inc.
    • 17.3.19. NeuroLogica Corporation
    • 17.3.20. Nova Biomedical
    • 17.3.21. Perkinelmer Inc.
    • 17.3.22. Quest Diagnostics Incorporated
    • 17.3.23. Siemens AG
    • 17.3.24. SuperSonic Imagine
    • 17.3.25. Werfen, S.A.
    • 17.3.26. OSI Systems, Inc.
    • 17.3.27. Hill-Rom Holdings, Inc.
    • 17.3.28. Bio-Rad Laboratories, Inc.
    • 17.3.29. Sekisui Diagnostics, LLC
    • 17.3.30. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. WOMEN'S HEALTH DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. WOMEN'S HEALTH DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. WOMEN'S HEALTH DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR CONDITIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY THYROID DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY THYROID DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVULATION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVULATION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVULATION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVULATION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVULATION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY OVULATION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT OF CARE INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT OF CARE INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT OF CARE INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT OF CARE INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT OF CARE INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY POINT OF CARE INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFORMATIONAL SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFORMATIONAL SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFORMATIONAL SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFORMATIONAL SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFORMATIONAL SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFORMATIONAL SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COLORIMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COLORIMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COLORIMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COLORIMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COLORIMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY COLORIMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY FLUOROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY FLUOROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY FLUOROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY FLUOROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY FLUOROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY FLUOROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITAL AND DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITAL AND DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITAL AND DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITAL AND DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITAL AND DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY HOSPITAL AND DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY PREGNANCY AND FERTILITY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS WOMEN'S HEALTH DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD